GVHD Clinical Trials and Biomarkers

$189,499P01FY2010CANIH

University Of Michigan At Ann Arbor, Ann Arbor MI

Investigators

Linked publications & trials

Paper 39222793 Paper 38968143 Paper 38640197 Paper 38640195 Paper 38548227 Paper 38324721 Paper 38320730 Paper 37142257 Paper 36350750 Paper 36095841 Paper 35703182 Paper 35643350 Paper 35443021 Paper 34669521 Paper 34474163 Paper 34471240 Paper 33201499 Paper 32582668 Paper 32020045 Paper 31779977 Paper 31738834 Paper 30504314 Paper 30482771 Paper 30399420 Paper 30201970 Paper 30176942 Paper 30106382 Paper 30087106 Paper 30057862 Paper 29545329 Paper 28951581 Paper 28581444 Paper 28484267 Paper 28194439 Paper 28017733 Paper 27625357 Paper 27416114 Paper 26873960 Paper 26687425 Paper 26551636 Paper 26386318 Paper 26359186 Paper 25972478 Paper 25729761 Paper 25687798 Paper 25455279 Paper 25125579 Paper 24527786 Paper 24492144 Paper 24295572 Paper 24046012 Paper 23924003 Paper 23892043 Paper 23760615 Paper 23290438 Paper 23205489 Paper 23200544 Paper 23165480 Paper 23149907 Paper 23065502 Paper 22955330 Paper 22889218 Paper 22469883 Paper 22286196 Paper 22226094 Paper 22155140 Paper 21979939 Paper 21384095 Paper 21270339 Paper 21195297 Paper 21091111 Paper 20371463 Paper 20302964 Paper 20113888 Paper 19812490 Paper 19282026 Paper 19147075 Paper 19041607 Paper 18832652 Paper 18721764 Paper 18541194 Paper 18502834 Paper 18460880 Paper 18411417 Paper 18042798 Paper 17950916 Paper 17786233 Paper 17365261 Paper 16478883 Paper 16440318 Paper 16289694 Paper 16125638 Paper 15753842 Paper 15625121 Paper 15446306 Paper 15258462 Paper 15205666 Paper 15205258 Paper 15187116 Paper 15148490

Abstract

PROJECT SUMMARY (See instructions): New treatments are needed for graft-vs-host disease (GVHD), the most serious complication of allogeneic bone marrow transplantation (BMT). Current pharmacologic agents for GVHD prevention and treatment primarily target one of the essential effectors for GVHD, donor T cells. Other key effectors for GVHD, and therefore potential therapeutic targets, are antigen presenting cells (APCs). Extensive experimental data developed by this PPG support the conduct of translational clinical trials to test agents that act upon this additional GVHD mechanism. We have demonstrated that APC function can be modulated by histone deacetylase inhibitors (HDACi) and in preliminary data we published, that the HDACi, suberoylanalide hydroxamic acid (SAHA), also known as vorinostat, regulates experimental GVHD. In this project will perform a unique clinical trial of this drug for GVHD prevention. A further advance in GVHD, the individualization of treatment, is presently hampered because GVHD can not be predicted precisely, the diagnosis is often hard to establish, and patients whose GVHD is likely to be resistant to standard therapy can not be identified. One of the first GVHD biomarker panels with predictive and diagnostic power was identified in work supported by this projecL We have recently identified multiple additional biomarkers using a large-scale proteomics discovery approach. In this project we will integrate newly discovered biomarkers with those already validated to create informative and clinically useful panels for allogeneic BMT patients. The Specific Aims are: 1. To conduct a Phase II trial using the HDACi, vorinostat in addition to standard immunosuppression to prevent GVHD in related donor reduced intensity transplantation 2. To develop biomarkers specific to GVHD target organs (skin and Gl tract). 3. To validate eight newly discovered candidate proteins as biomarkers for the diagnosis, prognosis and prediction of systemic acute GVHD. 4. To optimize predictive, diagnostic, and prognostic biomarker panels using validated combinations of target organ specific and systemic biomarkers and to analyze their value in new clinical trials.

View original record on NIH RePORTER →